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Summary
Italian hard cooked types of cheese, like Parmigiano Reggiano and Grana Padano, are 
characterised by positive nutritional qualities. In fact, they contain substances that have 
particular biological activities, and therefore they can be fully considered, according to the 
defi nition given by the European Unit, as ‘functional’ foods. This short review concisely 
describes these components and the benefi cial eff ects related to their activities. The de-
scription of the biologically active components has been organised in the following para-
graphs: protein and peptides, fat and lipids, carbohydrates and prebiotics, probiotic bacte-
ria, vitamins, mineral salts, and components of dairy products active in disease prevention. 
In particular, several known bioactive peptides were found in Parmigiano Reggiano cheese 
samples: for example, phosphopeptides, which are known for their mineral-binding ca-
pacity and vehiculation activity, peptides with immunomodulatory activity, and angioten-
sin-converting enzyme-inhibitory peptides with anti-hypertensive eff ects. Among lipids, 
the role of conjugated linoleic acid and other fatt y acids present in these cheese types was 
taken into consideration. The presence of oligosaccharides with prebiotic properties and 
probiotic bacteria was also described. Finally, particular emphasis was given to highly 
available calcium and its impact on bone health.
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Introduction
A study conducted at the INRAN (National Research 
Institute for Food and Nutrition, Rome, Italy) has led to the 
conclusion that it is simplistic to consider milk and dairy 
products exclusively as sources of essential nutrients (pro-
tein, calcium and vitamins) since it has been reported that 
milk and dairy products contain about 2000 molecules, some 
of which possess a specifi c biological activity (1). Among 
dairy foods, Italian hard cooked types of cheese, such as 
Parmigiano Reggiano and Grana Padano, are characterised 
by positive nutritional qualities. In fact, these cheese types 
contain substances that have particular biological activities, 
and therefore they can be fully considered, according to 
the defi nition given by the EU, as ‘functional’ foods, which 
are defi ned as ‘foods that contain bio logically active com-
ponents able to improve human health or reduce the risk 
of disease, or otherwise produce benefi cial eff ects on the 
health and welfare of the consumer’ (2). In this short re-
view, these components and the benefi cial eff ects related to 
their activities are succinctly described.
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Protein and Peptides
Proteins constitute about 33 % of Italian hard cooked 
types of cheese, presenting, from a quantitative perspec-
tive, the most important components of Parmigiano Reg-
giano and Grana Padano cheese. The proteins of these types 
of cheese are characterised by a high biological value. In 
fact, they contain high concentrations of all the essential 
amino acids. Amino acids such as isoleucine, leucine, 
lysine, threonine, tryptophan, valine, methionine, phenyl-
alanine, tyrosine and histidine are present in optimal 
amounts and in a particularly bioavailable form (2). In 
particular, the high content of lysine in cheese protein is 
noticeable, especially if compared with that of wheat, 
whose protein lacks this amino acid (3).
Besides this nutritional aspect, Italian hard cooked 
cheese proteins also have a capacity to be assimilated rel-
atively fast, since during ripening, a great percentage of 
them are hydrolysed into peptones, peptides and free 
amino acids by proteolytic enzymes, deriving both from 
milk and from the lactic acid bacteria that develop in the 
curd. This is similar to a predigestion, which leads to the 
formation of compounds with a progressively lower mo-
lecular mass until free amino acids are formed. At the end 
of this process, free amino acids constitute approx. 25 % 
of total nitrogen. Moreover, these low-molecular-mass 
peptides and free amino acids themselves play a role in 
the stimulation of both acid and pepsin gastric secretion, 
which further increases the digestion rate of proteins (4).
Overall, Italian hard cooked types of cheese are char-
acterised by a very varied composition of nitrogen com-
ponents. Apart from a variable amount of intact casein, 
they contain peptides of various length and free amino 
acids. During digestion, these three nitrogen components 
undergo a diff erent absorption (slow, accelerated and 
fast, respectively), allowing for a modulation in the utili-
sation of the protein substrate and its more effi  cient as-
similation from the diet (5).
Bioactive peptides: general description
The primary function of milk and dairy proteins is to 
supply the body with fundamental amino acids and or-
ganic nitrogen adequately. However, in addition to a nu-
tritional role, milk proteins have a physiological impor-
tance, being a source of biologically active peptides. This 
aspect has been studied since 1979, and numerous pep-
tides derived from milk proteins (αs1-casein, β-casein, κ - 
-casein, α-lactalbumin, β-lactoglobulin, immunoglobulins, 
lactoferrin, phosphoglycoproteins, transferrin and serum 
albumin), their sequence and biological activity have 
been determined. Some reviews are specifi cally devoted 
to this subject (6–11). Bioactive peptides (consisting of 
2–30 amino acid residues), encrypted in major milk pro-
teins, are latent and inactive until they are released and 
activated by enzymatic proteolysis, e.g. during gastroin-
testinal digestion or food processing (12). Aft er activation, 
they can act within the body by infl uencing physiological 
processes and modulating various biological functions 
(11).
As previously reported, during cheese ripening, milk 
caseins are fi rst hydrolysed by the action of milk proteas-
es, rennet proteases (only to a lesser extent in Italian hard 
cooked types of cheese, due to the almost complete dena-
turation of chymosin during the cooking phase) and the 
proteases and proteinases of lactic acid bacteria used as 
starters. The large fragments formed are then further de-
graded by proteolytic enzymes from the microbiota of 
both the whey starter and the milk. Lactic acid bacteria 
proteinases which, aft er lysis of the cell, are associated 
with the cell wall and intracellular peptidases are released 
in the curd and are responsible for the formation of small 
peptides and free amino acids. Digestive enzymes in the 
gastrointestinal tract (stomach and intestinal proteases 
and brush border peptidases) further hydrolyse oligopep-
tides, contributing to the formation of bioactive peptides 
(4). Thus, the enzyme-modifi ed cheese process, mainly 
designed to produce fl avour ingredients, may simultane-
ously produce bioactive peptides which are considered 
physiologically important (13).
Most of these studies on bioactive peptides were per-
formed on hydrolysed and digested casein or by adminis-
tering milk or generic dairy products to mice. However, 
as stated by Korhonen and Pihlanto (14), during cheese 
ripening, a great variety of peptides are formed, many of 
which have been shown to exert biological activities. So, it 
is reasonable to think that many of these bioactive pep-
tides can be produced also during the ripening of Parmi-
giano Reggiano and Grana Padano, mainly by lactic acid 
bacteria starters (15,16). In fact, one of the very specifi c 
species of whey starters used for Grana Padano and Par-
migiano Reggiano, Lactobacillus helveticus, is one of the 
species mainly responsible for the formation of these bio-
active compounds (17,18). Some studies (19,20) have in-
vestigated the formation of peptides in Parmigiano Reg-
giano and Grana Padano cheese and/or their digested 
products in vitro; however, this topic needs to be studied 
further, with particular emphasis on biopeptide forma-
tion. As att ested by Sforza et al. (20), several known bioac-
tive peptides were found to be present in Parmigiano 
Reggiano cheese samples; for example, phosphopeptides 
derived from the N-terminal part of β-casein, known for 
their mineral binding capacity and vehiculation activity 
(21), are present in Parmigiano Reggiano cheese aged for 
more than 16 months.
Bioactive peptides act in the body of mammals ac-
cording to mechanisms similar to hormones. The pep-
tides introduced with dietary cheese or produced by in-
testinal hydrolysis can reach the target sites in the luminal 
side of the gastrointestinal tract or, aft er being absorbed 
into the systemic circulation, the peripheral organs (9,10, 
12,22). These peptides may exert diff erent benefi cial phy-
siological functions: opioid peptides are opioid receptor 
ligands which can modulate absorption processes in the 
intestinal tract; ACE-inhibitory peptides are blood pres-
sure regulators and exert an antihypertensive eff ect; im-
munomodulating casein peptides stimulate the activities 
of the cells of the immune system; caseinophosphopep-
tides may function as carriers for diff erent minerals, espe-
cially calcium. Many of these peptides can have two or 
more diff erent biological activities (12). In the following 
paragraphs, the principal peptides derived from dairy 
protein and their biological functions are summarised, re-
ferring for a more detailed description to the specifi c re-
views.
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Opioid peptides
A number of milk protein peptides have been shown 
to behave like opioid receptor ligands able to address opi-
oidergic reactions in adults or in neonates. With respect to 
the proteins from which they are derived, these peptides 
have been named α-casein exorphins or casoxin D (α-ca-
sein), β-casomorphins or β-casorphin (β-casein), casoxin 
or casoxin A, B or C (κ-casein), and other coming from whey 
proteins that can be present in cheese only in a negligible 
amount (α-lactorphins from α-lactalbumin, β-lac torphin 
from β-lactoglobulin or lactoferroxins from lactoferrin). 
Only casoxins and lactoferroxins display antagonistic prop-
erties; the other peptides behave like opioid receptor ago-
nists (23).
β-Casomorphins were the fi rst milk protein-derived 
opioid receptor ligands whose amino acid sequences were 
identifi ed. It is thus conceivable that more information 
about this peptide group has been collected than about 
any other group of milk opioids. They were called β-caso-
morphins due to their morphine-like behaviour.
Teschemacher et al. (24) found that β-casomorphins 
arrive to the cardiovascular system aft er gastrointestinal 
digestion of milk or milk products in more than negligi-
ble amounts – at least in adult animals or humans; enzy-
matic degradation in the intestinal wall and in blood ap-
pears to prevent it. The authors have also described that 
these peptides can have a regulatory infl uence as ‘food 
hormones’, participating in the control of gastrointestinal 
functions in adults and neonates.
Immunomodulatory peptides
There is a substantial body of evidence according to 
which several of the biologically active peptides released 
by enzymatic hydrolysis of milk proteins are very potent 
immunoregulatory peptides (25), aff ecting cells of the im-
mune system, and consequently the downstream immu-
nological responses and cellular functions (25,26).
It was demonstrated that peptides from αs1-casein 
(residues 194–199 and 23–34) and β-casein (residues 63–
68 and 191–193) stimulate phagocytosis by murine perito-
neal macrophages and consequently exert a protective ef-
fect against Klebsiella pneumoniae infection in mice aft er 
intravenous treatment (25,27–31). The peptide αs1-casein 
(residues 23–34) was demonstrated to be produced in Par-
migiano Reggiano during ripening (19). Quantifi cation of 
this peptide is not given in the paper, but its presence is 
att ested at 6 months of ripening, probably produced by a 
chymosin cleavage.
The peptide isracidin (N-terminal sequence 1–23 of 
αs1-casein) has been found to protect mice against infec-
tions by Staphylococcus aureus and stimulate a phagocytic 
response in mice infected with Candida albicans (32). This 
peptide was found by Sforza et al. (20) in samples of Par-
migiano Reggiano cheese. The authors do not give a spe-
cifi c quantity of this peptide, but they write that it is prob-
ably produced by a chymosin cleavage and it is the most 
abundant in the group of peptides whose amount is de-
creased during cheese ripening. A fi gure in the paper at-
tests that the peptides of this group are still present, in 
low amounts, at 12–25 months of ripening.
β-Casomorphin-7 derived from β-casein was used as 
a possible immunostimulating substrate, since it is a lig-
and of opioid receptors that have also been found on the 
surface of human T-lymphocytes (33–35).
β-Casokinin-10 (residues 193–202 of β-casein) and 
another heptapeptide from β-casein (residues 177–183), 
such as residues 23–34 of bovine αs1-casein, have been 
found to inhibit angiotensin-converting enzyme (ACE), 
which may act on the immune system, preventing the 
breakdown of bradykinin (25,36). The latt er acts as a me-
diator of the acute infl ammatory process and is thus able 
to stimulate macrophages and enhance lymphocyte mi-
gration.
Regazzo et al. (37) found that β-casein (residues 193–
209), a long and hydrophobic peptide composed of 17 
amino acid residues, has immunomodulatory activity. 
This peptide was demonstrated by Sforza et al. (20) to be 
formed during Parmigiano Reggiano ripening and present 
in the cheese samples. The authors do not give a specifi c 
quantity of this peptide, but they write that it is probably 
produced by lactic acid bacteria proteases and that chy-
mosin itself is responsible for its production. This peptide 
is not formed during the early stage of cheese production, 
but its amount increases during ageing and it is present in 
a small amount from the start to the end of the ageing pe-
riod, indicating that its production continued throughout 
the ripening period.
Dipeptide (Tyr-Gly), which corresponds to a partial 
sequence in the primary structure of bovine κ-casein (res-
idues 38–39), was used for immunotherapy of human im-
munodefi ciency virus infection (35,38).
Caseinophosphopeptides
Casein phosphopeptides or caseinophosphopeptides 
(CPPs) are a mixture of phosphorylated peptides of dif-
ferent molecular mass formed in vivo when casein is de-
graded by proteolytic enzymes in the digestive tract (39). 
Phosphate residues, represented as serine esters, consti-
tute the anionic binding site for minerals such as calcium, 
iron and zinc and form with them soluble salts, increasing 
their intestinal bioavailability. Bouhallab and Bouglè (40) 
showed that a purifi ed phosphopeptide (β(1–25)) exhibits 
a positive eff ect on iron bioavailability in vivo, reporting 
its effi  ciency in the absorption and availability of iron and 
the mechanism involved.
Numerous studies show that caseinophosphopep-
tides, by means of a bond with calcium, make the latt er 
more soluble, improving its absorption and increasing its 
availability (41,42). This system of passive transport is the 
main way of absorption of the calcium requested for bone 
calcifi cation. Erba et al. (41) state that the positive eff ect of 
CPPs on passive calcium absorption seems to depend on 
the relative amounts of both CPPs and calcium in intesti-
nal lumen. In that study, the ratio CPPs/Ca=15 was identi-
fi ed as the most effi  cient to increase mineral transport.
Moreover, Aimutis (43) demonstrated that CCPs can 
possess an anticariogenic eff ect, i.e. have a role in the pre-
vention of dental caries. Tooth enamel is a polymeric sub-
stance consisting of crystalline calcium phosphate em-
bedded in a protein matrix. Dental caries develops as a 
result of acidic demineralisation (calcium and phospho-
rus solubilisation) of tooth enamel. CPP can form nano-
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clusters with amorphous calcium phosphate (ACP) at the 
tooth surface to provide a reservoir of calcium and phos-
phate ions to maintain a state of supersaturation on the 
surface of tooth enamel. This would buff er the pH of the 
plaque, and also provide ions for tooth enamel reminer-
alisation.
Recently, Catt aneo et al. (44) have found that casein 
phosphopeptides were released during in vitro gastroin-
testinal digestion of Grana Padano cheese samples aged 
13, 19 and 26 months.
The ACE-inhibitory peptides
ACE-inhibitory peptides deserve special mention. 
They are generated by the activity of specifi c enzymes 
that cut proteins like β-casein and κ-casein (45). The angi-
otensin-converting enzyme, called ACE, cuts the chain of 
angiotensin I, which is then converted into angiotensin II. 
Angiotensin II acts on several mechanisms that regulate 
blood pressure, such as vasoconstriction, sodium reab-
sorption, and aldosterone release. Moreover, angiotensin 
II acts by degrading bradykinin, which exerts a regulato-
ry role on vasodilation. All this leads to an increase in 
blood pressure. These biopeptides inhibit the function of 
the ACE, inducing a drop in both systolic and diastolic 
pressure; the same mechanism is activated by drugs be-
longing to the class of ACE-inhibitors.
Basiricò et al. (46) demonstrated for the fi rst time the 
presence of eight diff erent potent ACE-inhibitory pep-
tides in Parmigiano Reggiano cheese samples and in their 
relative intestinal digestate. In particular, VPP, IPP, LHL-
PLP and HLPLP were revealed in a water-soluble extract, 
and their total amount was in the range of 8.46 to 21.55 
mg per kg of cheese. The mass fraction of ACE-inhibitory 
peptides in the total peptide content of undigested water-
-soluble extract was 0.10 to 0.38 %. Aft er in vitro gastroin-
testinal digestion of this water extract, the same ACE-in-
hibitory peptides, along with the newly formed AYFYPEL 
and AYFYPE, were found. The total amount of ACE-in-
hibitory peptides in digested Parmigiano Reggiano sam-
ples was in the range of 1959.33 to 3122.52 mg/kg, and the 
mass fraction of ACE-inhibitory peptides in the total pep-
tides in digested water-soluble extract was 13.68 to 21.81 
%. At the end of the digestive process, the authors found 
relevant amounts of LHLPLP (2483.95 mg/kg) and HL-
PLP (58.97 mg/kg). Other detected peptides included the 
newly formed AYFYPEL (6.46 mg/kg) and AYFYPE (7.34 
mg/kg). Two of these peptides are Val-Pro-Pro (VPP) and 
Ile-Pro-Pro (IPP), in the amounts of 3.97 and 2.32 mg/kg, 
respectively: these peptides were found by Hata et al. (47) 
to be responsible for a marked decrease in blood diastolic 
and systolic pressure in patients with blood pressure 
problems.
Crippa et al. (48) conducted a randomised, double- 
-blind, placebo-controlled study on 30 subjects suff ering 
from hypertension, who presented pathological pressure 
values (maximum >140 and/or minimum >90 mm Hg). 
All patients received, at random, a dietary supplementa-
tion with Grana Padano (30 g daily) and placebo (ob-
tained with fl avoured bread mixed with fat and salt in the 
amounts equal to those of the cheese). Supplementing the 
diet with Grana Padano cheese resulted in a signifi cant 
reduction in systolic and diastolic blood pressure.
Recently, Bernabucci et al. (49) found ACE-inhibitory 
activity and antihypertensive eff ect of naturally formed 
bioactive peptides in a lyophilised water-soluble extract 
from 32-month-aged Parmigiano Reggiano and Grana Pa-
dano. They were evaluated in undigested and in vitro di-
gested water-soluble extracts and tested in 20 spontane-
ously hypertensive rats. Both Parmigiano Reggiano and 
Grana Padano water-soluble extracts showed a consistent 
ACE-inhibitory activity and IC50 value of Grana Padano 
water-soluble extract was lower than that of Parmigiano 
Reggiano. The in vitro enzymatic digestion of these water-
-soluble extracts did not signifi cantly aff ect IC50 values.
The presence of ACE-inhibitory peptides in undigest-
ed (and also in in vitro digested in the stomach and intes-
tine) Grana Padano samples was recently demonstrated 
also by Stuknytė et al. (50). The authors found the follow-
ing peptides in the undigested Grana Padano samples (in 
mg/kg): VPP 2.76, IPP 2.49, RYLG 0.07, HLPLP 0.23, LHL-
PLP 0.38, in total mass fraction of ACE-inhibitory pep-
tides of 5.93 mg/kg. Aft er gastric digestion, the following 
peptides were found (in mg/kg): VPP 2.85, IPP 1.22, RYLG 
1.72, HLPLP 0.71, in total mass fraction of ACE-inhibitory 
peptides of 6.50 mg/kg. Aft er intestinal digestion the fol-
lowing peptides were found (in mg/kg): HLPLP 4.64 and 
LHLPLP 306, in total mass fraction of ACE-inhibitory pep-
tides of 311 mg/kg. The authors affi  rm that, together with 
plasmin, proteinases and peptidases of Lactobacillus helve-
ticus spp., the main lactic acid bacterium present in the 
whey starter added to raw milk prior to renneting, are 
main ly responsible for this extensive proteolysis in Grana 
Padano cheese.
Parmigiano Reggiano protein and glucose tolerance
In a study published in Diabetologia, Tricò et al. (51) 
showed that the administration of a meal composed of 50 
g of Parmigiano Reggiano, a boiled egg, and 300 mL of 
water, 30 minutes prior the ingestion of a strong glucose 
load, has a hypoglycaemic eff ect in comparison with a con-
trol group that did not receive this meal. The authors ob-
served that proteins co-ingested with carbohydrates exert 
a hypoglycaemic eff ect on both normal subjects and sub-
jects with diabetes, through the enhancement of insulin 
secretion and a minor delay in gastric emptying.
Fat and Lipids
Milk and dairy fat is the most complex fat in the hu-
man diet, consisting of more than 400 distinct fatt y acid 
species (52). In dairy fat, short-, medium- and long-chain 
fatt y acids, odd-chain fatt y acids, branched chain fatt y ac-
ids, conjugated linoleic acids (CLA), ruminal trans fatt y 
acids (vaccenic acid), n-3 and n-6 fatt y acids are represent-
ed. Many of these fatt y acids are present in our diets in 
signifi cant amounts only from dairy products (53). In parti-
cular, dairy fat is a rich source of butyric acid (C4:0), CLA, 
cis- and trans-palmitoleic acid (C16:1), and the branched 
chain fatt y acid phytanic acid (C20:0). Some of these are 
present in dairy fat only in a small percentage, but these 
small amounts may still be biologically relevant, alone or 
within the context of other fatt y acids (53).
Fat is present in Italian hard cooked types of cheese 
from a minimum of 25.5 % to a maximum of 31.4 %, with 
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a mean value of 28.4 %, compatible with the defi nition of 
semi-fat cheese (4). The content of cholesterol is relatively 
low, amounting on average to 83–91 mg per 100 g of cheese.
Triglycerides present in Italian hard cooked types of 
cheese are characterised by more than 25 % of medium- and 
short-chain fatt y acids (from C4 to C10). These compounds 
are naturally more easily absorbed than long-chain fatt y 
acids (they do not need lipoprotein transportation) and 
provide very quick energy to the organism, as they follow 
diff erent ways of assimilation from long-chain fatt y acids 
(4,5).
Moreover, during the ripening of Italian hard cooked 
types of cheese, a partial lipolysis of fats occurs, which 
makes available a certain amount of fatt y acids in a free 
form, facilitating their absorption (4), in analogy with the 
process of protein fractionation to amino acids previously 
described.
In a review regarding the eff ects of foods rich in fat 
on human health, Kratz et al. (53) summarised various 
studies (54–58) demonstrating that dairy fat consumption 
is associated with markers of bett er metabolic health and 
that dairy fat may protect against metabolic dysfunction. 
Kratz et al. (53) suggested that a potential mechanism by 
which dairy fat may exert benefi cial eff ects on cardiomet-
abolic risk is the reduction of chronic infl ammation and 
lipid peroxidation, as suggested by Wang et al. (59) in a 
study showing that dairy fat intake is inversely related to 
infl ammation and oxidative stress in overweight adoles-
cents.
White et al. (60) demonstrated that medium-chain 
fatt y acids (and in particular capric acid) can induce the 
phenomenon of vasodilation in vitro and in vivo. More-
over, these compounds, along with short-chain fatt y ac-
ids, can help in increasing the body antioxidant defences 
(61). Even phospholipids can have antioxidant properties: 
Franson et al. (62) reported that sphingosine directly in-
hibits phospholipases A2 and D. A research by Yoshida et 
al. (63) demonstrated an inhibitory eff ect of phosphatidyl-
serine on iron-dependent lipid peroxidation. Gordon et al. 
(64) found that phosphorylethanoline inhibited superox-
ide anion, with a mechanism that was not due to inhibi-
tion of cellular superoxide generation but to scavenging 
of generated superoxide anion.
In the following paragraphs, some dairy fatt y acids of 
fats or groups of dairy fatt y acids that have shown partic-
ular benefi ts for human health are described.
Conjugated linoleic acids
The term conjugated linoleic acid (CLA) refers to a 
group of positional and geometric isomers of linoleic acid 
characterised by the presence of two conjugated double 
bonds. The CLA are present in abundance in animal 
products, especially in milk and cheese.
The main isomer in dairy fat is rumenic acid, cis-9, 
trans-11 CLA, which can represent from 79 to 94 % of the 
total CLA of dairy fat. The other isomer frequently found 
in dairy fat is the trans-10, cis-12 CLA. Numerous studies 
have highlighted the potential health benefi cial eff ects of 
these two fatt y acids.
There is increasing evidence that individual isomers 
of CLA may have unique biological or biochemical ef-
fects. In particular, some benefi cial eff ects of the trans-10, 
cis-12 CLA isomer in rodents were described. Body com-
position changes (reduced body fat, enhanced body wa-
ter, enhanced body protein, and enhanced body ash con-
tents) were associated with feeding the trans-10, cis-12 
CLA isomer (65). The trans-10, cis-12 CLA isomer also ex-
erts specifi c eff ects on adipocytes, in particular reducing 
the uptake of lipid by inhibiting the activities of lipopro-
tein lipase and stearoyl-CoA desaturase (66). These eff ects 
on body composition appear to be due in part to reduced 
fat deposition and increased lipolysis in adipocytes, pos-
sibly coupled with enhanced fatt y acid oxidation in both 
muscle cells and adipocytes (67). Moreover, trans-10, cis- 
-12 CLA inhibits preadipocyte diff erentiation, decreasing 
body fat accumulation (68). Park et al. (69) indicate that 
CLA prevents body fat accumulation and mass gain and 
that their dietary administration may be more eff ective in 
protecting against fat mass regain following mass loss 
than a mass loss treatment.
Other benefi cial eff ects are due to the presence of the 
other CLA isomer, the cis-9, trans-11 CLA. Pariza et al. (66) 
demonstrated that this isomer enhances growth and pro-
bably feeds effi  ciency in young rodents. Some other ben-
efi cial eff ects are due to the presence of both isomers or 
possibly to a synergy between them. Pariza et al. (66) 
showed that both the cis-9, trans-11 and trans-10, cis-12 
CLA isomers appear to be active in inhibiting carcinogen-
esis in animal models. Ip et al. (70) showed that the anti-
cancer effi  cacies of the two isomers (cis-9, trans-11 CLA 
and trans-10, cis-12 CLA) were very similar. With the admi-
nistration of both CLA, 6 weeks aft er carcinogen adminis-
tration in rats, the total number of premalignant lesions 
was reduced by 33–36 %; at 24 weeks, the total number of 
mammary carcinomas was reduced by 35–40 %. Also Masso - 
-Welch et al. (71) found an inhibition of angiogenesis by 
CLA, defi ned as ‘cancer chemopreventive agent’.
Antiatherogenic activity, antidiabetogenic eff ect and 
antiaggregant action, such as the capacity to stimulate bone 
mineralisation and immune response, regulate the aller-
genic responses and decrease hypertension, have also 
been suggested for these molecules (2). A retrospective 
case-control study conducted in Costa Rica demonstrated 
a strong inverse relationship between cis-9, trans-11 CLA 
in adipose tissue and the risk of myocardial infarction 
(72). In this study, the presence of the cis-9, trans-11 CLA 
acid in the adipose tissue was strongly connected to the 
consumption of dairy products. This suggested that CLA 
may play the role of protective factor when ingested by 
dairy products.
Prandini et al. (73) reported a content of 183 mg of cis-
-9, trans-11 CLA (+ trans-9, cis-11 CLA) per 100 g of Parmi-
giano Reggiano cheese (corresponding to 6.18 mg per g of 
fat) and 145 mg per 100 g of Grana Padano cheese (corre-
sponding to 5.22 mg per g of fat), while the same authors 
reported a content of 37.7 mg of trans-9, trans-11 CLA (+ 
trans-10, trans-12 CLA) per 100 g of Parmigiano Reggiano 
cheese (corresponding to 1.27 mg per g of fat) and 27.2 
mg per 100 g of Grana Padano cheese (corresponding to 
0.98 mg per g of fat).
Prandini et al. (74) also reported a total CLA value of 
385 mg per 100 g of fat in the same types of cheese, corre-
sponding to 1.06 mg per g of cheese (for a fat content of 
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27.43 g/100 g). CLA content markedly depends on animal 
feed; in fact, in conventional Grana Padano, its content is 
0.55 g per 100 g of total fatt y acids, while in organic Grana 
Padano it is higher, 0.86 g per 100 g of total fatt y acids 
(75).
Other fatt y acids potentially benefi cial for health
Kratz et al. (53) suggested that the butyric acid at the 
mass fraction typical of dairy product fat (4 %) can have 
relevant clinical eff ects on body mass and metabolic health. 
It also seems possible that butyrate consumption can have 
benefi cial eff ects on chronic infl ammation of the gastroin-
testinal tract. There is also experimental evidence (76) that 
butyric acid may lead to an increased synthesis of mela-
tonin and metallothionein, one of the major antioxidant 
proteins of plasma. It can also stimulate the secretion of 
apolipoprotein A–I and apolipoprotein B-100 (77), im-
proving the physiological homeostasis of cholesterol and 
plasma triglycerides. The content of butyric acid in Par-
migiano Reggiano cheese was reported by Sandri et al. 
(78), who found a value of 59 mg per 100 g of fat at 12 
months of ripening, while at 24 months of ripening the 
value increased to 144 mg per 100 g of fat, due to lipoly-
sis. Malacarne et al. (79) reported a butyric acid content in 
Parmigiano Reggiano of 3.4 (1 month), 17.5 (6 months), 
29.9 (12 months), 38.8 (18 months) and 71.0 (24 months) 
mg per 100 g of fat in the inner part of the wheel, while in 
the outer part of the wheel, where lipolysis is more accen-
tuated, from 6 months onwards values were higher: 3.8 (1 
month), 25.2 (6 months), 50.4 (12 months), 83.3 (18 
months) and 123.9 (24 months) mg per 100 g of fat.
Trans-palmitoleic acid was associated with a lower in-
cidence of diabetes (56). In particular, it should be noted 
that the consumption of full-fat dairy products has been 
directly and strongly associated with trans-palmitoleic 
acid levels in plasma phospholipids (56). Palmitoleic acid, 
in fact, plays an important role in the regulation of hepat-
ic lipogenesis and in the adipocyte lipogenesis. Therefore, 
the consumption of dietary fats rich with this fatt y acid 
can positively aff ect both energy homeostasis and meta-
bolic health. These considerations may be relevant, since 
full-fat dairy products are one of the few dietary sources 
of palmitoleic acid (53). The mass fraction of trans-palmi-
toleic acid in Parmigiano Reggiano was reported by Cast-
agnett i et al. (80), which was 0.08 g per 100 g of fat when 
catt le feed was fresh or preserved forage, while it was 0.11 
g per 100 g of fat when cows were fed fresh forage with 
integrated extruded whole linseed fl our.
Another fatt y acid of potential interest is phytanic 
acid, a branched chain fatt y acid (C20:0). This acid is char-
acterised by a C16 chain with four methyl groups as side 
chains att ached in positions 3, 7, 11 and 15 (81). There are 
a series of in vitro experiments suggesting that phytanic 
acid from fat of dairy products may be relevant for ener-
gy and glucose homeostasis (53). Unfortunately, so far, to 
our knowledge, amounts of phytanic acid in Parmigiano 
Reggiano or Grana Padano cheese have not been detect-
ed. A study (82) has been done on other types of cheese, 
less hard than Italian hard cooked cheese, as Emmental 
(167–303 mg per 100 g of lipids), Edam (288 mg per 100 g 
of lipids) and Gouda (256–265 mg per 100 g of lipids). 
Other studies have reported the content of phytanic acid 
in milk that is rather variable: Capuano et al. (83) reported 
an average content of 146 mg per 100 g of fat, but with 
oscillations between 65 and 328 mg per 100 g of fat; 
Schröder et al. (84) reported an average content of 116 mg 
per 100 g of lipids, but in organic milk the content was 
higher (153 mg per 100 g of lipids); Che et al. (85) regis-
tered the highest value in September (121 mg per 100 g of 
fat) and the lowest in May (96 mg per 100 g of fat), de-
pending also, to a great extent, on catt le feed, being higher 
with pasture (21–76 mg per 100 g of fat) than with maize 
silage (0–48 mg per 100 g of fat) and concentrate (10–34 
mg per 100 g of fat).
Carbohydrates and Prebiotics
Another important characteristic of Italian hard cooked 
cheese is the total absence of lactose, the main carbohy-
drate in milk. Lactose disappears in the early hours aft er 
the cheese making process. In fact, the fermentation of 
lactose into lactic acid and the subsequent acidifi cation of 
the curd is one of the most important processes in the 
production technology of Parmigiano Reggiano DOP and 
Grana Padano DOP. Based on the standards of the Euro-
pean Commission (April 2003), Parmigiano Reggiano and 
Grana Padano can be defi ned as ‘lactose-free’ products 
because they contain lactose in amounts not higher than 
0.10 mg per 100 kcal of product (86). The absence of lac-
tose in ripened cheese which is ready for consumption is 
a very important fact for subjects who are intolerant to 
this sugar or for individuals who, due to an insuffi  ciency 
of lactase enzyme, are unable to digest lactose. Lactose in-
tolerance is a very common disease among Asian popula-
tions, who historically do not consume milk and dairy 
products and consequently suff er from lactase defi ciency; 
Western populations suff er more oft en from some types 
of lactose malabsorption, and only occasionally of intoler-
ance. Lactose intolerance induces a reduction in calcium 
ingestion, sometimes below the requirements, as a conse-
quence of the elimination of milk and dairy products 
from the diet. Increasing evidence suggests that individu-
als with lactase defi ciency can reach an adequate level of 
calcium intake through Italian hard cooked cheese con-
sumption, thereby improving bone health and preventing 
osteoporosis (2).
Oligosaccharides with prebiotic properties
In the carbohydrate fraction of Italian hard cooked 
cheese, it is important to emphasise the presence of cer-
tain oligosaccharides, i.e. short-chain non-digestible car-
bohydrates with a possible prebiotic eff ect. In particular, 
these carbohydrates could stimulate the growth and/or 
activity of one or more bacterial populations in the colon, 
with specifi c health benefi ts. Prebiotics are defi ned as 
those food components which, resisting the acid environ-
ment of the stomach and the action of bile salts and diges-
tive enzymes in the small intestine, reach the colon, where 
they selectively stimulate the multiplication of existing 
benefi cial strains (bifi dobacteria and lactobacilli) and in-
duce local and systemic eff ects advantageous for the host 
(87,88).
Prebiotics act as a selective substrate for fermenta-
tions, infl uencing the microbial activity in the intestine 
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and the absorption of minerals, as well as stimulating the 
immune system (86). The oligosaccharides are also in-
volved in many cellular recognition processes and have 
numerous biological activities including immunostimula-
tory, anti-infl ammatory, antiviral and immunological func-
tion (89).
In a study carried out on a large number of samples 
of Parmigiano Reggiano, Coppa (87,90) demonstrated for 
the fi rst time the presence of a signifi cant proportion of 
oligosaccharides, compounds which can act as prebiotics 
able to favour the development of intestinal ‘bifi dogenic 
microbiota’. The analysis of the characterisation of the oli-
gosaccharides showed the presence of several peaks (over 
50), whose sequence was found to be very constant in all 
the examined samples (87). These peaks are considerably 
more numerous and substantially diff erent from those 
present in the cow’s milk employed for cheese produc-
tion; consequently, their presence in the fi nal product 
must be linked to the action of digestive-fermentative pro-
cesses that, taking place in various stages of the produc-
tion, could lead to the synthesis of new oligosaccharide 
molecules. The mass fraction of oligosaccharides in Par-
migiano Reggiano was approx. 2.5 g per 100 g.
The presence of glycosaminoglycans was also found 
in Parmigiano Reggiano cheese. This denomination iden-
tifi es a class of natural molecules active in the regulation 
of primary biological activities such as, among the many, 
cell interaction with growth factors and regulation of blood 
coagulation functions, showing at the same time anti-
thrombotic, antiviral and anti-infl ammatory activity (91).
Probiotic Bacteria
To be considered a probiotic, a bacterial strain must 
be a normal component of human intestinal microbiota, 
be absolutely safe for use in human beings, be active and 
vital under the conditions present in the intestine, be re-
sistant to gastrointestinal secretions (gastric juice, bile and 
pancreatic juice), and be able to persist, at least temporar-
ily, in the human gut. There is experimental evidence that 
some of the bacteria in Italian hard cooked cheese can 
have probiotic functions. In particular, it has been shown 
that, at 12 months of ripening, in Parmigiano Reggiano, 
the presence of Lactobacillus rhamnosus is still detectable, 
even if at low levels (103–104 CFU/g), having the actual 
characteristics of probiotic (92). Also, Pancaldi et al. (86) 
emphasise the probiotic nature of Parmigiano Reggiano 
and its possible use in the prevention of intestinal and ex-
traintestinal diseases at all ages, from infants to the elder-
ly.
Vitamins
Milk and cheese belong to food that in the daily ra-
tion covers only a small proportion of the vitamin re-
quirements. However, with reference to the values indi-
cated by the Recommended Levels of Nutrient Intake 
(LARN) for adults, 100 g of Parmigiano Reggiano com-
pletely cover the need for vitamin B12 and biotin, a third 
of the requirement of vitamin A and B2, and from 1/5 to 
1/10 of the requirements of other vitamins (4,5).
Mineral Salts
Italian hard cooked types of cheese also contain a large 
amount of macrominerals (namely calcium, phosphorus, 
sodium and chloride) and trace elements (particularly 
zinc and selenium). In particular, these types of cheese are 
a very important source of calcium, because of both their 
high content of this element (1159 mg per 100 g) and its 
particular bioavailability. The content of calcium in these 
types of cheese depends also on catt le breed, the milk of 
Italian Brown cows being richer in calcium than that of 
Italian Friesian cows (93).
Calcium, vitamin D and proteins are the three main 
nutrients that sustain the development and maintenance 
of bone structure. Many reports relating to the intake of 
these nutrients have emphasised their importance in the 
prevention of bone loss and thus in the reduction of the 
risk of fractures in the elderly (94). Being a source of cal-
cium and protein, dairy products could play a positive 
role on bone health (42). Perego et al. (95) have shown that 
casein phosphopeptides (produced by hydrolysis of Ital-
ian hard cooked cheese proteins, see Protein and Peptides 
section) can activate calcium uptake by intestinal cells. 
From this point of view, Italian hard cooked types of cheese 
can be very important foods for the skeleton bone growth: 
they represent an excellent source of many essential nutri-
ents for the skeletal development and health. The presence 
of proteins of high biological value and highly bioavail-
able calcium makes these types of cheese really ‘functional 
foods’ for treating bone homeostasis and for the preven-
tion of osteoporosis (42).
Recently, De Luca et al. (96) have demonstrated that 
gastrointestinal digestates of Grana Padano and Trentin-
grana cheese promote intestinal calcium uptake and ex-
tracellular bone matrix formation in vitro.
Among the trace elements, the presence of selenium 
and zinc in milk and Italian hard cooked cheese is of par-
ticular interest, since Se is the cofactor of glutathione per-
oxidase and Zn is the cofactor of the enzyme superoxide 
dismutase. Therefore, Se and Zn indirectly inhibit the ac-
tivity of the prooxidant iron and free radical in general. 
Moreover, they induce the synthesis of metallothionein 
and activate the ornithine decarboxylase for the synthesis 
of polyamines (61).
Components of Dairy Products and Disease 
Prevention
The last part of the review focuses on the components 
of Italian hard cooked cheese that can have a role in the 
prevention of some diseases. In the following paragraphs, 
the most important experimental evidence of this is suc-
cinctly exposed.
Dairy products can reduce the occurrence of type 2 
diabetes
Numerous studies have demonstrated a relationship 
between the consumption of dairy products, in particular 
of some of their constituents, and a reduction of diabetes 
occurrence.
Statistical studies have found that subjects who re-
ceived greater amounts of dairy products within their 
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diet decreased the risk of developing type 2 diabetes (DM2) 
by an average of 14 % (97,98). Also, Sluĳ s et al. (99) sug-
gest that increased consumption of cheese tends to be in-
versely associated with the risk of diabetes.
In a large prospective study, Malik et al. (100) showed 
that an increased consumption of dairy products during 
adolescence is signifi cantly associated with a reduced risk 
of type 2 diabetes in adulthood. This fi nding is in agree-
ment with the results from previous studies (101,102) per-
formed on adults, which showed inverse associations be-
tween the intake of dairy products and type 2 diabetes. 
Overall, there is evidence of the benefi cial eff ect of daily 
intake of dairy products on glucose homeostasis, indicat-
ing a possible benefi cial eff ect of dairy consumption in 
the prevention of the development of type 2 diabetes (97).
Recent literature suggests that the fatt y acids con-
tained in dairy products can exert a potential role in pre-
venting diabetes (56,99,103). In addition, dairy products 
are rich in calcium, vitamin D and magnesium, all con-
stituents that may exert a protective function against dia-
betes (102,104).
Some scientifi c studies have shown that the incidence 
of diabetes is inversely associated with dairy products 
with high fat content (56,100,103). Many researchers have 
suggested an association between the quality of fat, rather 
than the quantity, and diabetes risk. For example, cheese 
is a source of saturated fatt y acids; Hu et al. (105) suggest-
ed that these fatt y acids may be involved in reducing the 
risk of diabetes. However, based on Krachler et al. (103), 
the higher amount of odd-chain fatt y acids in dairy prod-
ucts too can lead to a diabetes risk reduction. Recently, 
Ericson et al. (106) detected an association between the 
presence of short-chain saturated fatt y acids, typical of 
dairy products, and the onset of diabetes protection. 
Dairy products are also the best sources of lauric acid 
(12:0) and myristic acid (14:0).
Dairy products can reduce symptoms of intestinal 
problems
Pancaldi et al. (86) presented three cases of infants 
suff ering from various forms of intestinal problems, sub-
jected to a special diet therapy, in order to resolve situa-
tions that would be diffi  cult to manage using special vari-
eties of infant formula on the market. These children were 
given a mixture consisting of 40 g of Parmigiano Reg-
giano aged for at least 36 months, 40 g of rice or corn and 
tapioca, 40 g of sugar, 10 g of corn oil, all added to 1 litre 
of water. This compound, known as NO (New Olivi, from 
the researcher who invented this composition), is able to 
provide about 60 kcal per 100 mL.
Aft er the introduction of the food based on Parmi-
giano Reggiano cheese, all cases showed a rapid and pro-
gressive relief of symptoms. In fact, Italian hard cooked 
types of cheese have a high concentration of easily ab-
sorbable amino acids and oligopeptides, similar to that of 
protein hydrolysates. As for the lipid component, medi-
um- and short-chain fatt y acids are directly absorbed in 
the intestine and immediately employed as a signifi cant 
source of energy. The use of Italian hard cooked cheese as 
food therapy is appropriate not only for their high nutri-
tional value, but also for their characteristics as functional 
food, which produce benefi cial eff ects on the gastrointes-
tinal tract. Moreover, their effi  cacy in pathological condi-
tions is further increased by the prebiotic and probiotic 
eff ects resulting from oligosaccharides and by the natural 
bacterial microbiota present in the Italian hard cooked 
cheese mass.
Dairy products can have a benefi cial role in metabolic 
syndrome
Dairy products as Italian hard cooked cheese may 
have a benefi cial role also in the alleviation of metabolic 
syndrome (98). This syndrome is a cluster of risk factors 
for increased mortality, including obesity, altered glucose 
homeostasis, hypertension and atherogenic dyslipidae-
mia. Individuals with metabolic syndrome oft en suff er 
from a chronic infl ammatory state.
Dairy products can regulate blood pressure
Epidemiological studies suggest that the consump-
tion of dairy products may be associated with a 13 % re-
duction of the risk of high blood pressure (98,107). The 
content of calcium and vitamin D, as well as some pep-
tides of milk (see the ACE-inhibitory peptides section), 
may exert a benefi cial eff ect on blood pressure by inhibit-
ing ACE, which modulates the endothelial function (108, 
109).
Dairy products can prevent cardiovascular diseases
Warensjö et al. (55) reported an inverse association 
between the intake of fat from dairy products and the risk 
factors for cardiovascular diseases including triglycer-
ides, total cholesterol, and insulin in the serum during 
fasting. A possible explanation may be that the intake of 
dairy fat reduces the risk of myocardial infarction through 
a mechanism which involves the reduction of fat and trig-
lycerides, and improves metabolic health.
Dairy products can prevent insurgence of colon cancer
Perego et al. (110) showed that casein phosphopep-
tides derived from dairy foods can prevent insurgence of 
colon cancer, protecting diff erentiated intestinal cells 
from calcium overload toxicity and prevent their apopto-
sis, favouring proliferation while inducing apoptosis in 
undiff erentiated tumour cells.
Conclusions
In this review, the functional properties of Italian 
hard cooked types of cheese were described, highlighting 
the eff ects of each component on human health. It ap-
pears that there are many important benefi ts related to 
the dietary intake of the components of these types of 
cheese, making these products truly valuable functional 
foods.
In particular, proteins in Italian hard cooked types of 
cheese possess biological properties att ributable to poten-
tially bioactive peptide sequences; these peptides, hidden 
and inactive in the primary protein structure, may be re-
leased and activated by proteolytic processes during the 
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technological treatment or during gastrointestinal diges-
tion and act in the body by infl uencing physiological 
processes and modulating various biological functions. In 
particular, several ACE-inhibitory peptides were found in 
Parmigiano Reggiano cheese samples and in their relative 
intestinal digestate. In particular, VPP, IPP, LHLPLP and 
HLPLP were revealed in water-soluble extract, while aft er 
in vitro gastrointestinal digestion of this water extract, the 
same ACE-inhibitory peptides along with the newly formed 
AYFYPEL and AYFYPE were found. Some of these pep-
tides are responsible for a marked decrease in blood di-
astolic and systolic pressure in patients with blood pres-
sure problems.
As far as lipid fraction is concerned, Italian hard cooked 
cheese can be an important source of fatt y acids, which 
appear to be particularly benefi cial to human health. 
Many of them are present in signifi cant amounts only in 
dairy products. In particular, Italian hard cooked cheese 
fat is a source of butyric acid (C4:0) (30–140 mg per 100 g 
of fat, depending on cheese ripening), CLA (385 mg per 
100 g of fat, corresponding to 1.06 mg per g of cheese, but 
variable according to catt le feed), trans-palmitoleic acid 
(tC16:1) (0.08–0.11 mg per 100 g of fat, depending on cat-
tle feed), and possibly also the branched chain fatt y acid 
phytanic acid (C20:0), but in this case the presence in Ital-
ian hard cooked cheese, att ested for other types of cheese, 
needs confi rmation. CLA may have unique and precious 
biological or biochemical eff ects: in particular, body com-
position changes (reduced body fat, enhanced body water, 
enhanced body protein, and enhanced body ash contents) 
were associated with CLA. They exert specifi c eff ects on 
adipocytes too, in particular reducing the uptake of lipid 
by inhibiting the activities of lipoprotein lipase and stea-
royl-CoA desaturase; moreover, CLA can prevent body 
fat accumulation and mass gain. Butyric acid can have 
relevant clinical eff ects on body mass and metabolic health 
and can have benefi cial eff ects on chronic infl ammatory 
conditions of the gastrointestinal tract. Trans-palmitoleic 
acid was associated with a lower incidence of diabetes, 
and phytanic acid may be relevant for energy and glucose 
homeostasis.
Italian hard cooked types of cheese are also charac-
terised by the presence of certain oligosaccharides, i.e. 
short-chain non-digestible carbohydrates, with a possible 
prebiotic eff ect, which could stimulate the growth and/or 
the activity of one or more bacteria in the colon, with spe-
cifi c health benefi ts and numerous biological activities 
such as immunostimulant, anti-infl ammatory, antiviral 
and immunological.
There is experimental evidence that some of the bac-
teria in the Parmigiano Reggiano cheese ripened for 12 
months are still present, even if at low levels, and can 
have probiotic functions. Vitamins are also present in Ital-
ian hard cooked cheese, even if some of them do not com-
pletely cover the recommended levels of nutrients (LARN) 
indicated by Italian Society of Human Nutrition (SINU).
Italian hard cooked cheese also contains a large 
amount of macrominerals (calcium, phosphorus, sodium, 
chloride) and trace elements (particularly zinc and seleni-
um). The particularly high content and bioavailability of 
calcium, together with the presence of vitamin D and spe-
cifi c proteins, make these types of cheese really ‘function-
al foods’ for bone homeostasis and for the prevention of 
osteoporosis.
Among all these properties, two in particular seem to 
be of great interest: the ability to keep blood pressure reg-
ulated, thanks to ACE-inhibitory peptides, and the possi-
bility of these types of cheese to act as foods rich in bio-
available calcium, especially for countries such as Asia, 
where osteoporosis in menopause is an increasingly im-
portant issue. This evidence needs to be highlighted to 
counteract the negative impact of the smear campaign 
against animal foods that are publicised to exert negative 
infl uence on human health.
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